Enzene is a biotech startup based in India, specializing in the development of clinical and biosimilar products. The company has a robust pipeline of products that are on the brink of being launched in both the Indian and global markets. Enzene's business model revolves around B2B licensing opportunities, offering its innovative products to other businesses in the region.

The company is driven by a team of world-class scientists who are dedicated to making a significant impact on human lives. Their leadership team is highly experienced, with decades of experience in the pharmaceutical industry and recognition from industry bodies such as the Indian Drug Association.

Enzene operates in the biotech and pharmaceutical market, serving clients in the healthcare sector. They generate revenue through the sales of their products, with 32% of their revenue coming from offshore sales.

The company is also committed to maintaining high standards of environmental, health, and safety (EHS) performance. They regularly conduct inspections, audits, and reviews to ensure compliance with regulatory and company standards. They also invest in training and communication to raise awareness and develop knowledge about EHS issues.

Enzene is a subsidiary of Alkem, one of the top ten pharmaceutical companies in India. Alkem has a strong portfolio of over 800 brands and more than 1,300 SKUs across a wide range of therapy segments.

Keywords: Biotech, Clinical Products, Biosimilar Products, B2B Licensing, Pharmaceutical Industry, Environmental Health and Safety, Offshore Sales, Healthcare Sector, Alkem, Indian Market.